Open AccessStudy of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis
Author(s) -
Prem Kotian
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/17061.7021
Subject(s) - zoledronic acid , medicine , osteoporosis , tolerability , bisphosphonate , myalgia , adverse effect , population , environmental health
Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis.